Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Phio Pharmaceuticals ( (PHIO) ) has provided an announcement.
On December 23, 2025, Phio Pharmaceuticals announced that the U.S. Food and Drug Administration had accepted the nonclinical protocol study design for PH-762, allowing the company to begin an FDA-required toxicology study in the first quarter of 2026 ahead of a potential pivotal human trial. The company is simultaneously working to secure commercially viable PH-762 drug product that meets current Good Manufacturing Practices in 2026, funded in part by recent financing, and reported encouraging interim data from its ongoing Phase 1b dose-escalation trial in skin cancer patients, with multiple complete and partial responses, no clinical disease progression, and no dose-limiting toxicities observed to date, underscoring both the clinical potential of PH-762 and a meaningful de-risking step in its development pathway.
The most recent analyst rating on (PHIO) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Phio Pharmaceuticals stock, see the PHIO Stock Forecast page.
Spark’s Take on PHIO Stock
According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.
Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.
To see Spark’s full report on PHIO stock, click here.
More about Phio Pharmaceuticals
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biopharmaceutical company specializing in siRNA-based immuno-oncology therapeutics built on its proprietary INTASYL gene silencing technology. Its lead program, PH-762, targets the PD-1 gene to enhance immune-mediated killing of cancer cells, and is being evaluated as a potential non-surgical treatment for skin cancers including cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma.
Average Trading Volume: 2,932,149
Technical Sentiment Signal: Sell
Current Market Cap: $11.52M
See more insights into PHIO stock on TipRanks’ Stock Analysis page.